RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000094.xml
Z Gastroenterol 2024; 62(01): 73-109
DOI: 10.1055/a-2189-8461
DOI: 10.1055/a-2189-8461
Leitlinie
S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
Schlusselwörter
Hepatozelluläres Karzinom - HCC - hepatobiliäre Karzinome - Leberzellkarzinom - Leber - Diagnostik - Therapie - Risikofaktoren - PräventionPublikationsverlauf
Eingereicht: 06. Oktober 2023
Angenommen: 11. Oktober 2023
Artikel online veröffentlicht:
09. Januar 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022 https://pubmed.ncbi.nlm.nih.gov/21374666/
- 2 Brouwer WP, van der Meer AJP, Boonstra A. et al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24: 1023-1031 DOI: 10.1111/jvh.12727?download=true.
- 3 Papatheodoridis G, Dalekos G, Sypsa V. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806 https://www.sciencedirect.com/science/article/pii/S0168827815007953?via%3Dihub
- 4 Kanwal F, Kramer JR, Asch SM. et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020; 71: 44-55 DOI: 10.1002/hep.30823?download=true.
- 5 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36: 1239-1251 DOI: 10.1111/liv.13142?download=true.
- 6 Papatheodoridis GV, Chan HL, Hansen BE. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967 https://air.unimi.it/retrieve/handle/2434/437611/717191/1-s2.0-S0168827815000045-main.pdf
- 7 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155: 1828-1837.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279617/pdf/nihms-1504451.pdf
- 8 Simeone JC, Bae JP, Hoogwerf BJ. et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017; 9: 679-688 https://pubmed.ncbi.nlm.nih.gov/29276410/
- 9 Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study. Liver Int 2022; 42 (04) 820-828 https://pubmed.ncbi.nlm.nih.gov/35152526/
- 10 Inoue M, Yoshimi I, Sobue T. et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293-300 https://pubmed.ncbi.nlm.nih.gov/15713964/
- 11 Bravi F, Tavani A, Bosetti C. et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26: 368-377
- 12 Aleksandrova K, Bamia C, Drogan D. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102: 1498-508 http://spiral.imperial.ac.uk/bitstream/10044/1/29882/11/Am%20J%20Clin%20Nutr-2015-Aleksandrova-1498-508.pdf
- 13 Setiawan VW, Wilkens LR, Lu SC. et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148: 118-125; quiz e15 https://pubmed.ncbi.nlm.nih.gov/25305507/
- 14 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422 https://link.springer.com/content/pdf/10.1007%2Fs00432-004-0552-0.pdf
- 15 Pocha C, Dieperink E, McMaken KA. et al. Surveillance for hepatocellular cancer with ultrasonography vs computed tomography -- a randomised study. Aliment Pharmacol Ther 2013; 38: 303-312 DOI: 10.1111/apt.12370.
- 16 Trinchet JC, Chaffaut C, Bourcier V. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997 DOI: 10.1002/hep.24545.
- 17 Tzartzeva K, Obi J, Rich NE. et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718.e1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927818/pdf/nihms940431.pdf
- 18 Ioannou GN, Beste LA, Green PK. et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157: 1264-1278.e4 https://www.sciencedirect.com/science/article/abs/pii/S001650851941130X?via%3Dihub
- 19 Song BG, Sinn DH, Chi S. et al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30: 1447-1452
- 20 Burrel M, Llovet JM, Ayuso C. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042 DOI: 10.1002/hep.1840380430.
- 21 Haradome H, Grazioli L, Tinti R. et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69-78 DOI: 10.1002/jmri.22588.
- 22 Di Martino M, De Filippis G, De Santis A. et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23: 887-896 https://link.springer.com/content/pdf/10.1007%2Fs00330-012-2691-z.pdf
- 23 Schellhaas B, Bernatik T, Bohle W. et al. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study. Ultraschall Med 2021; 42 (02) e20 https://pubmed.ncbi.nlm.nih.gov/32717752/
- 24 Strobel D, Jung E, Ziesch M. et al. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study. Eur Radiol 2021; 31 (10) 7614-7625 https://pubmed.ncbi.nlm.nih.gov/33855588/
- 25 Schellhaas B, Bernatik T, Dirks K. et al. Contrast-Enhanced Ultrasound Patterns for the Non-invasive Diagnosis of Hepatocellular Carcinoma: A Prospective Multicenter Study in Histologically Proven Liver Lesions in a Real-Life Setting Demonstrating the Benefit of Extended Late Phase Observation. Ultrasound Med Biol 2021; 47 (11) 3170-3180 https://pubmed.ncbi.nlm.nih.gov/34417066/
- 26 Khalili K, Kim TK, Jang HJ. et al. Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-738 https://www.sciencedirect.com/science/article/pii/S0168827810008147?via%3Dihub
- 27 Chan AC, Fan ST, Poon RT. et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15: 439-448 https://www.hpbonline.org/article/S1365-182X(15)31417-9/pdf
- 28 Chevret S, Trinchet JC, Mathieu D. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141 https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
- 29 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322258/pdf/zlj550.pdf
- 30 Kitai S, Kudo M, Minami Y. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90 https://www.karger.com/Article/Abstract/173428
- 31 Leung TW, Tang AM, Zee B. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769 DOI: 10.1002/cncr.10384.
- 32 Marrero JA, Fontana RJ, Barrat A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-716 https://pubmed.ncbi.nlm.nih.gov/15795889/
- 33 Pinato DJ, Sharma R, Allara E. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66: 338-346 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30535-9/pdf
- 34 Vitale A, Saracino E, Boccagni P. et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41: 1260-1263 https://www.sciencedirect.com/science/article/pii/S0041134509004850?via%3Dihub
- 35 Yau T, Tang VY, Yao TJ. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700.e3 https://www.gastrojournal.org/article/S0016-5085(14)00243-1/pdf
- 36 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236 https://www.sciencedirect.com/science/article/pii/S0168827818302150
- 37 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 DOI: 10.1056/NEJM199603143341104?articleTools=true.
- 38 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 https://www.sciencedirect.com/science/article/pii/S1470204508702845?via%3Dihub
- 39 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
- 40 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52: 143-149 DOI: 10.1080/00365521.2016.1236396.
- 41 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67: 381-400 DOI: 10.1002/hep.29485.
- 42 Sneiders D, Houwen T, Pengel LHM. et al. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102: 88-96
- 43 Wong T, Lee V, Law A. et al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology 2021; 74 (05) 2580-2594 https://pubmed.ncbi.nlm.nih.gov/34091914/
- 44 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 2017; 67 (01) 92-99 https://pubmed.ncbi.nlm.nih.gov/28257902/
- 45 Degroote H, Callebout E, Iesari S. et al. Extended criteria for liver transplantation in hepatocellular carcinoma A retrospective, multicentric validation study in Belgium. Surg Oncol 2019; DOI: 10.1016/j.suronc.2019.10.006. https://pubmed.ncbi.nlm.nih.gov/31630912/
- 46 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21: 1142-1152 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/113108/lt24169.pdf?sequence=1
- 47 Chen MS, Li JQ, Zheng Y. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448947/pdf/20060300s00006p321.pdf
- 48 Feng K, Yan J, Li X. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802 https://www.sciencedirect.com/science/article/pii/S0168827812003613?via%3Dihub
- 49 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912
- 50 Ng KKC, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104: 1775-1784 DOI: 10.1002/bjs.10677.
- 51 Yin L, Li H, Li AJ. et al. Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61: 82-88 https://www.sciencedirect.com/science/article/pii/S0168827814001561?via%3Dihub
- 52 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60 DOI: 10.1055/s-0030-1247132.
- 53 Di Costanzo GG, Tortora R, D'Adamo G. et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30: 559-565 DOI: 10.1111/jgh.12791.
- 54 Cucchetti A, Piscaglia F, Cescon M. et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46: 257-263
- 55 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432
- 56 Liu H, Wang ZG, Fu SY. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103: 348-356 DOI: 10.1002/bjs.10061.
- 57 Endo K, Kuroda H, Oikawa T. et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53: 1575-1583 DOI: 10.1080/00365521.2018.1548645.
- 58 Lo CM, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 DOI: 10.1053/jhep.2002.33156.
- 59 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf
- 60 Golfieri R, Giampalma E, Renzulli M. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264 https://iris.unito.it/retrieve/handle/2318/149077/25760/art%20Doxorubicina-Tace%202014.pdf
- 61 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1: Cd011313
- 62 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 2018; 50: 751-760 DOI: 10.1055/s-0043-124870.
- 63 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27: 2031-2041 https://link.springer.com/content/pdf/10.1007%2Fs00330-016-4548-3.pdf
- 64 Casadei Gardini A, Tamburini E, Inarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321 https://www.dovepress.com/getfile.php?fileID=45631
- 65 Sapir E, Tao Y, Schipper MJ. et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018; 100: 122-130 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818982/pdf/nihms942371.pdf
- 66 Eriguchi T, Takeda A, Tateishi Y. et al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021; 51 (07) 813-822 https://pubmed.ncbi.nlm.nih.gov/33856722/
- 67 Rim C, Lee J, Kim S. et al. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis. JHEP Rep 2023; 5 (01) 100594 https://pubmed.ncbi.nlm.nih.gov/36561128/
- 68 Craig T, Xiao Y, McNulty S. et al. Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. Pract Radiat Oncol 2022; DOI: 10.1016/j.prro.2022.11.013. https://pubmed.ncbi.nlm.nih.gov/36581199/
- 69 Rim C, Kim H, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131: 135-144 https://pubmed.ncbi.nlm.nih.gov/30773180/
- 70 Brunner T, Bettinger D, Schultheiss M. et al. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021; 11: 653141 https://pubmed.ncbi.nlm.nih.gov/33816309/
- 71 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 DOI: 10.1056/NEJMoa1915745?articleTools=true.
- 72 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 https://www.sciencedirect.com/science/article/pii/S1470204508702857?via%3Dihub
- 73 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
- 74 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389: 56-66
- 75 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379: 54-63 DOI: 10.1056/NEJMoa1717002?articleTools=true.
- 76 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
- 77 Facciorusso A, Tartaglia N, Villani R. et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res 2021; 13 (04) 2379-2387 https://pubmed.ncbi.nlm.nih.gov/34017396/
- 78 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 DOI: 10.1056/NEJMoa0708857?articleTools=true.
- 79 Marrero JA, Kudo M, Venook AP. et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-1147 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30346-4/pdf
- 80 Ganten TM, Stauber RE, Schott E. et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23: 5720-5728 https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf
- 81 Leal CRG, Magalhães C, Barbosa D. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36: 911-918 DOI: 10.1007/s10637-018-0621-x.
- 82 Pressiani T, Boni C, Rimassa L. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406-411 https://www.annalsofoncology.org/article/S0923-7534(19)36863-2/pdf
- 83 Ogasawara S, Chiba T, Ooka Y. et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33: 729-739 https://link.springer.com/article/10.1007%2Fs10637-015-0237-3
- 84 Kudo M, Matilla A, Santoro A. et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021; 75 (03) 600-609 https://pubmed.ncbi.nlm.nih.gov/34051329/
- 85 Yau T, Park J, Finn R. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23 (01) 77-90 https://pubmed.ncbi.nlm.nih.gov/34914889/
- 86 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-1636 https://www.sciencedirect.com/science/article/abs/pii/S1470204517306836
- 87 Chow PKH, Gandhi M, Tan SB. et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36: 1913-1921 https://www.ncbi.nlm.nih.gov/pubmed/29498924
- 88 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64: 1090-1098 https://www.ncbi.nlm.nih.gov/pubmed/26809111
- 89 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565-575 https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(17)30156-5.pdf
- 90 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66 https://www.sciencedirect.com/science/article/pii/S0140673616324539?via%3Dihub
- 91 Finn R, Ryoo B, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38 (03) 193-202 https://pubmed.ncbi.nlm.nih.gov/31790344/
- 92 Rao Q, Li M, Xu W. et al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020; 14 (05) 765-775 https://pubmed.ncbi.nlm.nih.gov/32572818/
- 93 Parikh N, Marshall A, Betts K. et al. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res 2021; 10 (05) 343-352 https://pubmed.ncbi.nlm.nih.gov/33442996/
- 94 He S, Jiang W, Fan K. et al. The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021; 11: 626984 https://pubmed.ncbi.nlm.nih.gov/33833987/
- 95 Kudo M, Finn R, Edeline J. et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022; 167: 1-12 https://pubmed.ncbi.nlm.nih.gov/35364421/
- 96 Yau T, Kang Y, Kim T. et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020; 6 (11) e204564 https://pubmed.ncbi.nlm.nih.gov/33001135/
- 97 Haun MW, Estel S, Rucker G. et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017; 6: CD011129 http://www.ncbi.nlm.nih.gov/pubmed/28603881
- 98 Adler K, Schlieper D, Kindgen-Milles D. et al. [Integration of palliative care into intensive care: Systematic review]. Anaesthesist 2017; 66: 660-666 http://www.ncbi.nlm.nih.gov/pubmed/28589374
- 99 Dalgaard KM, Bergenholtz H, Nielsen ME. et al. Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome. Palliat Support Care 2014; 12: 495-513 http://www.ncbi.nlm.nih.gov/pubmed/24621947
- 100 Davis MP, Temel JS, Balboni T. et al. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4: 99-121 http://www.ncbi.nlm.nih.gov/pubmed/26231807
- 101 Hui D, Kim YJ, Park JC. et al. Integration of oncology and palliative care: a systematic review. Oncologist 2015; 20: 77-83 http://www.ncbi.nlm.nih.gov/pubmed/25480826
- 102 Hui D, Meng YC, Bruera S. et al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist 2016; 21: 895-901 http://www.ncbi.nlm.nih.gov/pubmed/27185614
- 103 Tassinari D, Drudi F, Monterubbianesi MC. et al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016; 11: 63-71 http://www.ncbi.nlm.nih.gov/pubmed/26464077
- 104 Gärtner U, Braun GD, Held K. et al. [Physical complaints, stress and quality of life of oncologic patients Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91: 501-508
- 105 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK. Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Version 2.2. 2020. https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
- 106 Atchison EA, Gridley G, Carreon JD. et al. Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 2011; 128: 635-643 DOI: 10.1002/ijc.25362?download=true.
- 107 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32: 441-448 DOI: 10.1111/j.1478-3231.2011.02614.x?download=true.
- 108 El-Serag HB, Engels EA, Landgren O. et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of US veterans. Hepatology 2009; 49: 116-123 DOI: 10.1002/hep.22606?download=true.
- 109 Huang Y, You L, Xie W. et al. Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8: 100570-100581 https://www.oncotarget.com/article/20141/pdf/
- 110 Jing W, Jin G, Zhou X. et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21: 24-31
- 111 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804834/pdf/nihms363811.pdf
- 112 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017; 17: 149 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721586/pdf/12876_2017_Article_696.pdf
- 113 Park JY, Hong SP, Kim YJ. et al. Long-term follow up of gallbladder polyps. J Gastroenterol Hepatol 2009; 24: 219-222 DOI: 10.1111/j.1440-1746.2008.05689.x?download=true.
- 114 Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014; 39: 745-750 DOI: 10.1111/apt.12655?download=true.
- 115 Zhang H, Zhu J, Ke F. et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int 2015; 2015: 497942 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569758/pdf/BMRI2015-497942.pdf
- 116 De Moura DTH, Moura EGH, Bernardo WM. et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis. Endosc Ultrasound 2018; 7: 10-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838722/pdf/EUS-7-10.pdf
- 117 Navaneethan U, Hasan MK, Lourdusamy V. et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc 2015; 82: 608-614 e2 https://www.ncbi.nlm.nih.gov/pubmed/26071061
- 118 Becker NS, Rodriguez JA, Barshes NR. et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12: 117-122 DOI: 10.1007/s11605-007-0335-4.
- 119 Darwish MuradS, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.e3; quiz e14 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846443/pdf/nihms507180.pdf
- 120 Zhen Y, Liu B, Chang Z. et al. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019; 12: 4489-4498 https://pubmed.ncbi.nlm.nih.gov/31239717/
- 121 Mosconi C, Solaini L, Vara G. et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021; 44 (05) 728-738 https://pubmed.ncbi.nlm.nih.gov/33709272/
- 122 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20: 663-673 https://www.sciencedirect.com/science/article/abs/pii/S147020451830915X?via%3Dihub
- 123 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 DOI: 10.1056/NEJMoa0908721?articleTools=true.
- 124 Okusaka T, Nakachi K, Fukutomi A. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939781/pdf/6605779a.pdf
- 125 Valle JW, Furuse J, Jitlal M. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25: 391-398
- 126 Park JO, Oh DY, Hsu C. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015; 47: 343-361 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509359/pdf/crt-2014-308.pdf
- 127 Markussen A, Jensen L, Diness L. et al. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial. Cancers (Basel) 2020; 12 (07) DOI: 10.3390/cancers12071975. https://pubmed.ncbi.nlm.nih.gov/32698410/
- 128 Oh D, Ruth He A, Qin S. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 2022; 1: EVIDoa2200015 DOI: 10.1056/EVIDoa2200015.
- 129 Abou-Alfa G, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21 (05) 671-684 https://pubmed.ncbi.nlm.nih.gov/32203698/
- 130 Maio M, Ascierto P, Manzyuk L. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33 (09) 929-938 https://pubmed.ncbi.nlm.nih.gov/35680043/
- 131 Lamarca A, Palmer D, Wasan H. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701 https://pubmed.ncbi.nlm.nih.gov/33798493/
- 132 Zhu A, Macarulla T, Javle M. et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021; 7 (11) 1669-1677 https://pubmed.ncbi.nlm.nih.gov/34554208/
- 133 Choi I, Kim K, Lee J. et al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer 2021; 154: 288-295 https://pubmed.ncbi.nlm.nih.gov/34303267/
- 134 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK. Entwicklung von leitlinienbasierten Qualitätsindikatoren Methodenpapier für das Leitlinienprogramm Onkologie, Version 21. 2017. https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik
- 135 Agopian VG, Harlander-Locke MP, Ruiz RM. et al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266: 525-535
- 136 Ashoori N, Bamberg F, Paprottka P. et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion 2012; 86: 338-348
- 137 Beal EW, Dittmar KM, Hanje AJ. et al. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front Oncol 2016; 6: 143
- 138 Boteon A, Boteon YL, Vinuela EF. et al. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. Clin Transplant 2018; 32: e13255
- 139 Cascales-Campos P, Martinez-Insfran LA, Ramirez P. et al. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?. Transplant Proc 2018; 50: 591-594 https://www.sciencedirect.com/science/article/abs/pii/S0041134517309284
- 140 Finkenstedt A, Vikoler A, Portenkirchner M. et al. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016; 36: 688-695 DOI: 10.1111/liv.12966.
- 141 Gabr A, Abouchaleh N, Ali R. et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017; 93: 100-106 https://www.sciencedirect.com/science/article/abs/pii/S0720048X17302012
- 142 Györi GP, Felsenreich DM, Silberhumer GR. et al. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017; 49: 236-243 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653748/pdf/10353_2017_Article_487.pdf
- 143 Habibollahi P, Shamchi SP, Choi JM. et al. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. J Vasc Interv Radiol 2019; 30: 323-329 https://www.sciencedirect.com/science/article/pii/S105104431831741X?via%3Dihub
- 144 Jianyong L, Jinjing Z, Lunan Y. et al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017; 7: 41624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290748/pdf/srep41624.pdf
- 145 Lu DS, Yu NC, Raman SS. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137
- 146 Nicolini A, Martinetti L, Crespi S. et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 327-332
- 147 Oligane HC, Xing M, Kim HS. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 2017; 282: 869-879
- 148 Sandow T, Pavlus J, Field D. et al. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019; 30: 995-1003
- 149 Tan CHN, Yu Y, Tan YRN. et al. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?. Ann Hepatobiliary Pancreat Surg 2018; 22: 27-35
- 150 Werner JD, Frangakis C, Ruck JM. et al. Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2019; 17: 638-643
- 151 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 2017; 67: 92-99
- 152 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809192/pdf/nihms667031.pdf
- 153 Nishikawa H, Inuzuka T, Takeda H. et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 143 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260104/pdf/1471-230X-11-143.pdf
- 154 Wang JH, Wang CC, Hung CH. et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-418 https://www.journal-of-hepatology.eu/article/S0168-8278(11)00524-1/fulltext
- 155 Peng ZW, Lin XJ, Zhang YJ. et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022-1033
- 156 Hasegawa K, Kokudo N, Makuuchi M. et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-729 https://www.sciencedirect.com/science/article/pii/S016882781200877X?via%3Dihub
- 157 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 193-200 DOI: 10.1111/jgh.12441.
- 158 Miura JT, Johnston FM, Tsai S. et al. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015; 17: 896-901 https://www.hpbonline.org/article/S1365-182X(15)31122-9/pdf
- 159 Zhang M, Ma H, Zhang J. et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2017; 10: 4829-4839 https://pubmed.ncbi.nlm.nih.gov/29042794/
- 160 Zhang QB, Zhang XG, Jiang RD. et al. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. Int J Hyperthermia 2017; 33: 255-262 DOI: 10.1080/02656736.2016.1257824?needAccess=true.
- 161 Liu PH, Hsu CY, Hsia CY. et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. Ann Surg 2016; 263: 538-545 https://www.ingentaconnect.com/content/wk/sla/2016/00000263/00000003/art00040;jsessionid=1n53m5b4ljd7b.x-ic-live-01
- 162 Takayasu K, Arii S, Sakamoto M. et al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 2018; 38: 484-493 DOI: 10.1111/liv.13670.
- 163 Uhlig J, Sellers CM, Stein SM. et al. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 2019; 29: 2679-2689 DOI: 10.1007/s00330-018-5902-4.
- 164 Hung HH, Chiou YY, Hsia CY. et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9: 79-86 https://www.cghjournal.org/article/S1542-3565(10)00847-5/pdf
- 165 Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7: 214-221
- 166 Lü MD, Kuang M, Liang LJ. et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2006; 86: 801-805
- 167 Lupo L, Panzera P, Giannelli G. et al. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?. HPB (Oxford) 2007; 9: 429-434
- 168 Abu-Hilal M, Primrose JN, Casaril A. et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 1521-1526
- 169 Tashiro H, Aikata H, Waki K. et al. Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011; 104: 3-9
- 170 Kim JW, Shin SS, Kim JK. et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol 2013; 14: 626-635
- 171 Tang C, Shen J, Feng W. et al. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016; 95: e3754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902444/pdf/medi-95-e3754.pdf
- 172 Bholee AK, Peng K, Zhou Z. et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol 2017; 19: 844-852
- 173 Pan T, Mu LW, Wu C. et al. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer 2017; 8: 3506-3513 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687165/pdf/jcav08p3506.pdf
- 174 Zhang R, Shen L, Zhao L. et al. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018; 24: 219-224 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045511/pdf/dir-24-4-219.pdf
- 175 Llovet JM, Real MI, Montana X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 https://www.sciencedirect.com/science/article/pii/S014067360208649X?via%3Dihub
- 176 Lin DY, Liaw YF, Lee TY. et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology 1988; 94: 453-456 https://www.sciencedirect.com/science/article/abs/pii/0016508588904362?via%3Dihub
- 177 Pelletier G, Roche A, Ink O. et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184
- 178 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261 DOI: 10.1056/NEJM199505113321903?articleTools=true.
- 179 Bruix J, Llovet JM, Castells A. et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-1583 DOI: 10.1002/hep.510270617?download=true.
- 180 Pelletier G, Ducreux M, Gay F. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial Groupe CHC. J Hepatol 1998; 29: 129-134
- 181 Stefanini GF, Amorati P, Biselli M. et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma An Italian experience. Cancer 1995; 75: 2427-2434 DOI: 10.1002/1097-0142%2819950515%2975%3A10%3C2427%3A%3AAID-CNCR2820751007%3E3.0.CO%3B2-J?download=true.
- 182 Bronowicki JP, Vetter D, Dumas F. et al. Transcatheter oily chemoembolization for hepatocellular carcinoma A 4-year study of 127 French patients. Cancer 1994; 74: 16-24 DOI: 10.1002/1097-0142%2819940701%2974%3A1%3C16%3A%3AAID-CNCR2820740105%3E3.0.CO%3B2-V?download=true.
- 183 Kim JH, Yoon HK, Kim SY. et al. Transcatheter arterial chemoembolization vs chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29: 1291-1298 DOI: 10.1111/j.1365-2036.2009.04016.x?download=true.
- 184 Herber S, Otto G, Schneider J. et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30: 1156-1165 DOI: 10.1007/s00270-007-9032-7.
- 185 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634
- 186 Georgiades CS, Hong K, D'Angelo M. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659 https://www.sciencedirect.com/science/article/pii/S1051044307607933?via%3Dihub
- 187 Okazaki M, Higashihara H, Koganemaru H. et al. Transcatheter arterial embolization for inoperable hepatocellular carcinoma. Jpn J Clin Radiol 1991; 36: 535-539
- 188 Sacco R, Bargellini I, Bertini M. et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-1552
- 189 van Malenstein H, Maleux G, Vandecaveye V. et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-376 https://www.karger.com/Article/Pdf/329602
- 190 Dhanasekaran R, Kooby DA, Staley CA. et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480 DOI: 10.1002/jso.21522?download=true.
- 191 Ferrer Puchol MD, la Parra C, Esteban E. et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53: 246-253 https://www.sciencedirect.com/science/article/abs/pii/S0033833810003449?via%3Dihub
- 192 Wiggermann P, Sieron D, Brosche C. et al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17: Cr189-Cr195 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/pdf/medscimonit-17-4-cr189.pdf
- 193 Song MJ, Chun HJ, Song DS. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250
- 194 Megías Vericat JE, García Marcos R, López Briz E. et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. Radiologia 2015; 57: 496-504 https://www.sciencedirect.com/science/article/abs/pii/S0033833815000764?via%3Dihub
- 195 Kloeckner R, Weinmann A, Prinz F. et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460638/pdf/12885_2015_Article_1480.pdf
- 196 Facciorusso A, Mariani L, Sposito C. et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31: 645-653 DOI: 10.1111/jgh.13147?download=true.
- 197 Baur J, Ritter CO, Germer CT. et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med 2016; 8: 69-74 https://pubmed.ncbi.nlm.nih.gov/27382341/
- 198 Gao S, Yang Z, Zheng Z. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60: 813-820
- 199 Huang K, Zhou Q, Wang R. et al. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 920-925 DOI: 10.1111/jgh.12439?download=true.
- 200 Zhou X, Tang Z, Wang J. et al. Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med 2014; 7: 3892-3903
- 201 Zou JH, Zhang L, Ren ZG. et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 2016; 17: 510-517 DOI: 10.1111/1751-2980.12380?download=true.
- 202 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48: 571-577
- 203 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
- 204 Mazzaferro V, Sposito C, Bhoori S. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826-1837 DOI: 10.1002/hep.26014?download=true.
- 205 Hilgard P, Hamami M, Fouly AE. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749 DOI: 10.1002/hep.23944?download=true.
- 206 Kulik LM, Carr BI, Mulcahy MF. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81 DOI: 10.1002/hep.21980?download=true.
- 207 Coelen RJS, Roos E, Wiggers JK. et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2018; 3: 681-690 https://www.sciencedirect.com/science/article/abs/pii/S2468125318302346?via%3Dihub
- 208 Celotti A, Solaini L, Montori G. et al. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur J Surg Oncol 2017; 43: 1628-1635
- 209 Ba Y, Yue P, Leung JW. et al. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma. Endosc Int Open 2020; 8: E203-E210 DOI: 10.1055/a-0990-9114.
- 210 Ramanathan R, Borrebach J, Tohme S. et al. Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma. J Gastrointest Surg 2018; 22: 1950-1957 DOI: 10.1007/s11605-018-3861-3.
- 211 Cai Y, Tang Q, Xiong X. et al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. Biosci Trends 2017; 11: 319-325 https://www.jstage.jst.go.jp/article/bst/11/3/11_2017.01107/_pdf
- 212 Farges O, Regimbeau JM, Fuks D. et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013; 100: 274-283 DOI: 10.1002/bjs.8950?download=true.
- 213 Xiong JJ, Nunes QM, Huang W. et al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol 2013; 19: 8731-8739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870521/pdf/WJG-19-8731.pdf
- 214 Wang L, Lin N, Xin F. et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. World J Surg Oncol 2019; 17: 116 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612106/pdf/12957_2019_Article_1656.pdf
- 215 Wronka KM, Grąt M, Stypułkowski J. et al. Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma. J Clin Med 2019; 8: 458 https://res.mdpi.com/d_attachment/jcm/jcm-08-00458/article_deploy/jcm-08-00458.pdf
- 216 Kishi Y, Shimada K, Nara S. et al. The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy. Langenbecks Arch Surg 2016; 401: 503-511 DOI: 10.1007/s00423-016-1427-y.
- 217 Nakai Y, Yamamoto R, Matsuyama M. et al. Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study. J Gastroenterol Hepatol 2018; 33: 1146-1153 DOI: 10.1111/jgh.14050?download=true.
- 218 Komaya K, Ebata T, Yokoyama Y. et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017; 161: 394-404
- 219 Kim KM, Park JW, Lee JK. et al. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage. Gut Liver 2015; 9: 791-799 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625710/pdf/gnl-09-791.pdf
- 220 Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56: 835-841
- 221 Paik WH, Park YS, Hwang JH. et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69: 55-62
- 222 Smith AC, Dowsett JF, Russell RC. et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
- 223 Speer AG, Cotton PB, Russell RC. et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
- 224 De Palma GD, Galloro G, Siciliano S. et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553
- 225 Saluja SS, Gulati M, Garg PK. et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6: 944-950.e3 https://www.sciencedirect.com/science/article/abs/pii/S1542356508003418?via%3Dihub
- 226 Sangchan A, Kongkasame W, Pugkhem A. et al. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012; 76: 93-99
- 227 Cheng JL, Bruno MJ, Bergman JJ. et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 2002; 56: 33-39
- 228 Lee TH, Moon JH, Choi JH. et al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc 2019; 90: 222-230 https://www.sciencedirect.com/science/article/abs/pii/S0016510719301737?via%3Dihub
- 229 Uberoi R, Das N, Moss J. et al. British Society of Interventional Radiology: Biliary Drainage and Stenting Registry (BDSR). Cardiovasc Intervent Radiol 2012; 35: 127-138 10.1007/s00270-011-0103-4
- 230 Paik WH, Lee TH, Park DH. et al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial. Am J Gastroenterol 2018; 113: 987-997
- 231 Bang JY, Navaneethan U, Hasan M. et al. Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos). Gastrointest Endosc 2018; 88: 9-17
- 232 Ortner ME, Caca K, Berr F. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363 https://www.sciencedirect.com/science/article/abs/pii/S0016508503013623?via%3Dihub
- 233 Zoepf T, Jakobs R, Rosenbaum A. et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001; 54: 763-766
- 234 Zoepf T, Jakobs R, Arnold JC. et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430
- 235 Pereira SP, Jitlal M, Duggan M. et al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open 2018; 3: e000379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069917/pdf/esmoopen-2018-000379.pdf
- 236 Kahaleh M, Mishra R, Shami VM. et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6: 290-297 https://www.sciencedirect.com/science/article/abs/pii/S1542356507011469?via%3Dihub
- 237 Gonzalez-Carmona MA, Bolch M, Jansen C. et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol Ther 2019; 49: 437-447 DOI: 10.1111/apt.15050?download=true.
- 238 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80: 794-804
- 239 Wentrup R, Winkelmann N, Mitroshkin A. et al. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver 2016; 10: 470-475 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849702/pdf/gnl-10-470.pdf
- 240 Dolak W, Schwaighofer H, Hellmich B. et al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J 2017; 5: 104-110 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384559/pdf/10.1177_2050640616654037.pdf
- 241 Tal AO, Vermehren J, Friedrich-Rust M. et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6: 13-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921441/pdf/WJGE-6-13.pdf